Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Manchester, UK, 26 November 2024 Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical study of MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to […]
Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Manchester, UK, 19 November 2024 Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), is pleased to announce the addition of three distinguished experts to its Scientific Advisory Board (SAB). Leading the SAB as the new chairperson is Dr Mark Treherne, a research scientist with […]
Monument Therapeutics Secures £1M Investment To Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Manchester, UK, 15 October 2024 Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation. The new investment builds on equity and non-dilutive funding announced in April 2024 and will support the clinical development of MT1988, a novel treatment for the cognitive symptoms of […]
